Trials / Completed
CompletedNCT02161146
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of AGN-229666 for the prevention of allergen-mediated conjunctivitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-229666 | One drop of AGN-229666 in the eye on Days 1 and 15. |
| DRUG | Vehicle to AGN-229666 | One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15. |
| DRUG | Olopatadine | One drop of olopatadine in the eye on Days 1 and 15. |
Timeline
- Start date
- 2014-06-04
- Primary completion
- 2014-12-20
- Completion
- 2014-12-20
- First posted
- 2014-06-11
- Last updated
- 2019-04-17
- Results posted
- 2016-03-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02161146. Inclusion in this directory is not an endorsement.